Product
Lutetium[177Lu] Oxodotreotide
Aliases
177Lu-DOTA0-Tyr3-Octreotate, Lutetium[177Lu] Oxodotreotide Injection
3 clinical trials
2 indications
Indication
Neuroendocrine TumorsIndication
Advanced Neuroendocrine NeoplasmClinical trial
A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With Inoperable, Progressive, , Well Differentiated, Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine TumoursStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Clinical Study to Evaluate the Safety and Efficacy of Lutetium[177Lu] Oxodotreotide Injection in Patients With Advanced Somatostatin Receptor Positive Neuroendocrine NeoplasmsStatus: Not yet recruiting, Estimated PCD: 2027-06-01
Clinical trial
Phase II Study to Evaluate the Efficacy and Safety of 177Lu-Dotatate in the First-line Treatment of Inoperable Patients With Locally Advanced or Metastatic, Somatostatin Receptor-positive G2 or G3 Gastroenteropancreatic Neuroendocrine TumorsStatus: Not yet recruiting, Estimated PCD: 2025-06-05